PharmX Technologies Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Tom Culver

Geschäftsführender

AU$219.3k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	87.3%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Tom Culver im Vergleich zu den Einnahmen von PharmX Technologies verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$219k	AU$191k	AU$95k

Vergütung im Vergleich zum Markt: TomDie Gesamtvergütung ($USD142.51K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD297.98K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Tom mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Tom Culver

less than a year

Amtszeit

AU$219,292

Vergütung

Mr. Tom Culver serves as Head of Wealth & Crypto Services at Douugh Limited since January 2021. Mr. Culver is Goodments Founder & CEO. Mr. Culver is Chief Executive Officer of PharmX Technologies Limited f...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Tom Culver	Chief Executive Officer	less than a year	AU$219.29k	keine Daten
Zoe Hillier	Chief Financial Officer	3.3yrs	AU$276.23k	0.10% A$ 43.1k
James Nevile	Chief Operating Officer	3.3yrs	AU$310.49k	0% A$ 0
Sally McDow	Company Secretary	no data	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: PHXDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jayne Shaw	Independent Non-Executive Director	4.1yrs	AU$97.68k	0.46% A$ 191.9k
Andrew Jonathan Newbery	Non-Executive Director	4.8yrs	AU$185.37k	0.29% A$ 118.2k
Philip England	Non-Executive Chairman	5yrs	AU$324.28k	4.51% A$ 1.9m
Alexander Mellis	Non-Executive Independent Director	less than a year	keine Daten	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: PHXDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

PharmX Technologies Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

Recent updates

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Less than half of directors are independent

Less than half of directors are independent

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

New major risk - Market cap size

Less than half of directors are independent

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

No independent directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

No independent directors

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

Now 20% undervalued

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

No independent directors

Corum Group Limited Launches Pharmxchange Platform

No independent directors

No independent directors

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

No independent directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

No independent directors

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit